Antibody therapy before phase 3 clinical approval, administration of elderly and high-risk patients… Participated in 35 medical institutions
On the morning of the 15th, the stock price fell 5.95% from the previous day… Securities Price “We need to consider whether sales will continue after approval”
![Celltrion's COVID-19 antibody treatment, Rekironaju. [사진=연합뉴스]](https://i0.wp.com/news.google.com/news/photo/202101/80976_57752_2033.jpg?resize=550%2C367&ssl=1)
[News Quest = Reporter Kim Bo-min]The government’s announcement that Celltrion’s’Rekironaju’ is first administered to elderly and high-risk patients before phase 3 clinical trials is drawing attention from the public.
As such, Celltrion’s share price has been declining day after day from the day before the 15th, despite the increased possibility that Celltrion will win the title of’Korea’s No. 1 antibody treatment for Corona 19′.
As such, stock market experts advised that it is necessary to observe whether or not it is possible to continue sales and profitability.
At a regular briefing on the 14th, the Central Defense Countermeasure Headquarters (Bang Dae-bon) gave priority to Celltrion’s antibody treatment,’Reekyronaju’ (ingredient name Legdanbimab, code name CT-P59), to elderly and high-risk patients prior to the conditional approval of Phase 3 clinical trials. He announced that he would be conducting a test to administer medication.
Accordingly, Celltrion is conducting research on some Corona19 patients with 35 medical institutions and 75 researchers with the cooperation of the Korean Infectious Society. Celltrion is responsible for the cost.
In addition, the quarantine authorities will evaluate whether the antibody treatment is effective against mutant viruses originating in the UK and South Africa.
Currently, Celltrion has applied for a conditional approval for phase 3 clinical trials of Rekirona to the Ministry of Food and Drug Safety, and announced the results of phase 2 clinical trials that Rekirona has reduced the incidence of severe patients by 54%.
![On December 22 last year, a researcher is looking at a COVID-19 antibody treatment in a laboratory at Incheon Celltrion Plant 2, which is developing an antibody treatment for a novel coronavirus infection (Corona 19). [사진=연합뉴스]](https://i0.wp.com/news.google.com/news/photo/202101/80976_57755_2653.jpg?resize=550%2C366&ssl=1)
Unlike the government, the quarantine authorities, and the industry as well as interest in Rekkirona, Celltrion’s stock price is on the decline every day.
Celltrion’s stock price is trading at 331,500 won, which is 21,000 won (-5.96%) down from the previous day at 10:10.
At the same time, Celltrion Healthcare is trading at 14,7500 won, an 8400 won (-5.39%) drop compared to the previous day, and Celltrion Pharmaceuticals at 193,000 won, down 13,500 won (-6.52%).
Regarding this situation, some securities experts analyzed that investors are carrying out’new opinion’ and said that it is necessary to carefully examine Celltrion’s future prospects.
An official at a securities company said, “Celltrion can become a leading indicator of other domestic treatments in the future, so expectations within the industry are rising.”
He then emphasized, “It is time to observe whether or not the sales persistence and profitability after approval, rather than giving meaning to approval itself.”
On the other hand, a meeting of the verification advisory group regarding Celltrion’s Rekkirona state is scheduled on the 17th, but the schedule for consultation with the Central Pharmacist Review Committee (Central Pharmacy) is still undecided.
However, as the Ministry of Food and Drug Safety (Ministry of Food and Drug Safety) announced the reduction of the approval review period to within 40 days, considering the urgency of the Corona 19 situation, it is likely that the approval will be decided by the 6th of next month.
Copyright © NewsQuest Unauthorized reproduction and redistribution prohibited